HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 22, No 04, April 2018 – Digestive health in the 21st century - Trust your guts       » Food wasted in China could feed 30-50 million       » Chinese scientists analyze human brain's "CPU"       » $150,000 fundraiser launched to sequence South Asian genomes       » Green tea-based drug carriers improve cancer treatment       » Scientists grow liver cancer cells in lab      
EYE ON CHINA
Neovia Enrolls First Patient in Cancer Trial for Immunotherapy Enhancing Drug
BEIJING – Neovia Oncology (Beijing, Taiwan, & Seattle), has begun its first Phase 1 clinical trial for its lead cancer drug NEV-801, a novel, multi-inhibitor drug able to enhance immunotherapy response in patients with advanced drug-resistant cancers.

During its pre-clinical proof-of-concept studies, conducted in China and America, NEV-801 showed exciting potential, including curative effects, to treat Chronic Myeloid Leukaemia that had become resistant to the gold-standard therapy (imatinib), as well as advanced colon cancer that had become resistant to multiple therapies.

No bone-marrow toxicity or gastro-intestinal side effects were observed at the highest administered doses in pre-clinical studies.

The initial clinical trial will be run by principal investigators in America at Dana Farber Cancer Institute, Boston; and Sarah Cannon Research Institute, Nashville. Neovia also plans studies in China in the near future.

Immunotherapy rarely controls clinically significant tumours that fail to express target antigens, and thereby fail to elicit an effective immune response. However, there is mounting evidence that tumour antigen production can be precisely stimulated to promote immune recognition and response.

NEV-801 is a conjugated compound made from an alkaloid isolated from the Chinese tree Camptotheca acuminate and podophyllotoxin derived from the roots of the may apple plant that grows in the wild in North America. Combined, it becomes a simultaneous multi-inhibitor of Topoisomerase I and Topoisomerase II activity, HIF-1 transcriptional activation, and hypoxic induction of VEGF mRNA and protein expression, targeting Werner syndrome protein (WRN) (a RecQ helicase), thereby overcoming MDR gene 1-mediated resistance. The simultaneous inhibition of multiple cancer pathways forces distressed tumours to express target antigens, thereby potentially enhancing the efficacy of immunotherapy.

"Patient enrolment marks the formal beginning of a clinical trial and so we are excited to get underway after much preparation and hard work by our team," said Gerald Su, COO, "This is the first program to have advanced through Neovia's innovative development pipeline that includes more than 60 potential drugs. It represents a milestone in the transition of Neovia to clinical-stage and validates us to potential investors and partners who can now help us grow and provide more potential therapies to cancer patients."

Neovia Oncology is developing safe, multi-inhibitor cancer drugs that enhance immune response to overcome drug resistance and seeks partners and investors for growth. ( www.neoviaoncology.com )

Source: Neovia Oncology Ltd

Click here for the complete issue.

NEWS CRUNCH  
news Shire, Microsoft and EURORDIS form Global Commission to accelerate time to diagnosis for children with rare diseases
news EmTech Asia explores future of life, humanity and economy
news Biology of Ageing II - Impactful Interventions
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2018
January:
Obesity / Outlook for 2018
February:
Searching for the fountain of youth
March:
Women in Science - Making a difference
April:
Digestive health in the 21st century - Trust your guts
May:
Asthma / Dental health
June:
Oncology / Biotech landscape in APAC
July:
Water management / Vaccination
August:
Regenerative medicine / Biotech start ups
September:
Digital healthcare / 3D printing
October:
Bones / Breast cancer
November:
Liver health / Top science research nations & institutions
December:
AIDS / Breakthrough of the year/Emerging trends
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2018 World Scientific Publishing Co Pte Ltd  •  Privacy Policy